Keith Stewart, MB, ChB
Medical Director, Mayo Clinic Center for Individualized Medicine
Dr. Keith Steward is a consultant in the Division of Hematology-Oncology at the Mayo Clinic campus in Arizona; newly appointed director of the Mayo Clinic Center for Individualized Medicine; and recognized as the Vasek and Anna Maria Polak Professor of Cancer Research.
Dr. Stewart received an M.B., Ch.B. degree at Aberdeen University Medical School in the United Kingdom, and an MBA degree at the University of Western Ontario. He completed an internship at Glasgow Royal Infirmary in the United Kingdom; a residency in internal medicine at Queens University in Ontario; a fellowship in hematology at the University of Toronto; and a fellowship in research at New England Medical Center in Boston.
He has more than 20 years of sustained national funding for laboratory research programs focusing on biology, genomics and individualized treatment of multiple myeloma; and has led numerous clinical trials of treatment drugs for multiple myeloma.
Dr. Stewart is active in Mayo Clinic education and mentoring; and holds full faculty privileges in Molecular Pharmacology and Experimental Therapeutics. He served as Dean for Research in Arizona; Chair of the Arizona Research Operations Management Team; and was a member of the Arizona Executive Operations Team and Clinical Practice Committees.
He has received numerous awards and honors, including being named the Scott-Whitmore Chair in Hematology and Gene Therapy. He has been conferred by the University of Toronto and Castle Connolly Medical Ltd, named in Canada’s Top 40 Under 40, and named one of America’s Top Doctors.
Dr. Stewart has authored more than 200 journal articles, abstracts, and publications. He serves on the Scientific Advisory Board for the Multiple Myeloma Research Foundation; and holds memberships with numerous professional organizations, including the Royal College of Physicians and Surgeons of Canada, the National Cancer Institute, the American Society of Clinical Oncology, the American Society of Hematology, and the Leukemia & Lymphoma Society.
Minnesota Public Radio
Bio coming soon.
C. Anthony Altar, Ph.D.
Senior Vice President and Chief Science Officer, Assurex Health, Inc.
Dr. C. Anthony Altar is an early member of AssureRx Health, Inc. As Senior Vice President, Neurosciences, he is responsible for the research of pharmacogenomic products.
Before joining the Assurex Health, Inc., team, Dr. Altar directed the Alzheimer's Diagnostic Laboratory for the Blanchette Rockefeller Neuroscience Institute. Dr. Altar earned a B.S. with Honors in Psychobiology from UCLA and a Ph.D., with Honors in Psychology from UC Santa Barbara.
As a postdoctoral scientist at UC Irvine, Dr. Altar created digital imaging of receptor-drug binding in the brain and while at UC Irvine, and Ciba-Geigy, he identified the serotonin/dopamine receptor binding profile of atypical antipsychotics. At Genentech and Regeneron Pharmaceuticals, Dr. Altar pioneered research of neurotrophic factors, and was the first to discover roles for BDNF in serotonin function, pain, and depression.
As global director for neuroscience at Otsuka, Dr. Altar led the team that discovered Abilify, its likely uses in psychosis, depression and bipolar illness, and helped lead the effort in its FDA approval. His teams at Psychiatric Genomics Inc. used genomics to discover the insulin-deficiency of schizophrenia and validated drug targets for this approach. He launched the Biomarkers Consortium within the Foundation for NIH.
Dr. Altar has published 135 neuroscience and drug discovery articles in peer-reviewed journals including Science and Nature.
Stephen Ansell, M.D., Ph.D.
Professor of Medicine, Mayo Clinic
Dr. Stephen Ansell is a consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic. He holds the academic rank of Professor of Medicine, Mayo Clinic College of Medicine. Dr. Ansell received his M.D. and Ph.D. at the University of Pretoria, South Africa and trained in Medical Oncology before coming to the United States. Dr. Ansell completed a residency in Internal Medicine and a fellowship in Hematology and Oncology at Mayo Clinic.
Dr. Ansell’s clinical practice interests focus on non-Hodgkin lymphoma, Hodgkin’s disease, and Waldenstrom’s macroglobulinemia. His research focuses on the biology of the disease, and on developing new therapies. He receives funding for research from the National Institutes of Health, the Leukemia and Lymphoma Society, and the International Waldenstrom’s Macroglobulinemia Foundation.
Dr. Ansell is Chair of the Mayo Clinic Lymphoma Group as well as Chair of the Faculty Development and Recruitment for Hematology at Mayo Clinic. He has been honored with various awards, including the Department of Medicine New Investigator at Mayo Clinic and Medical Honoree at the Lymphoma Research Foundation, Minnesota Chapter. He held memberships with the American Association for Cancer Research, the American Medical Association, the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group.
Dr. Ansell has served on the editorial boards of the American Journal of Hematology, Journal of Clinical Oncology, Blood Cancer Journal and Clinical Lymphoma and Myeloma. He has co-authored more than 234 articles in peer-reviewed journals.
Vincenzo Costigliola, M.D.
Founder and President of European Medical Association
Dr. Vincenzo Costigliola received his medical degree from the university of Naples and an honors diploma in Anesthesiology and Intensive Care from the University of Pisa. In addition, Dr. Costigliola has completed studies in Rheumatology, Dermatology, Proctology, Surgery, Drug Abuse, Emergency Treatment, Disaster Action, Hospital Organization, Medical Teaching Methodology, and Computer and Audio-Visual Training for the Medical Profession.
Dr. Costigliola is President of the European Association for Predictive, Preventive, and Personalized Medicine and President of the European Depression Association. He is a Board member of the European Biotechnology Association and a member of the International Advisory Board at King Abdulaziz University in Saudia Arabia. He was selected as expert evaluator in the 5th Framework Program and is the Associate Editor of the European Association for Predictive, Preventive, and Personalized Medicine Journal.
Dr. Costigliola is fluent in Italian, French, English, and Spanish.
Joshua Denny, M.D.
Associate Professor of Biomedical Infomatics and Associate Professor of Medicine, Vanderbilt University Medical Center
Dr. Joshua Denny is an Associate Professor in the Departments of Biomedical Informatics and Medicine at Vanderbilt University Medical Center. He completed an internal medicine residency as a Tinsley Harrison Scholar at Vanderbilt.
Dr. Denny’s interests in medical informatics began while in medical school with the development of a concept-based curriculum database to improve medical education. Currently, he focuses on applications of algorithms to accurately identify phenotypes from EMR data, and utilizing this date to discover genome-phenome associations to better understand disease risk and drug response. Dr. Denny and his lab have developed the Phenome-wide Association Study method applied to EMRs to rapidly uncover genetic pleiotropy and highlight potential drivers of genetic associations with endophenotypes.
Dr. Denny helps lead efforts for local and network pharmacogenetics implementation activities including Vanderbilt PREDICT that has tested more than 14,000 individuals to provide genetic-tailored therapy recommendations. He is a member of the Electronic Medical Records and Genomics network, Pharmacogenomics Research Network, a principal investigator in the Implementing Genomics in Practice networks, and is a principal investigator of other grants exploring phenomics, EHR data mining, natural language processing, and medical education.
Dr. Denny is a past recipient of the American Medical Informatics Association New Investigator, Homer Warner award, and the Vanderbilt Chancellor Award for Research. He remains active in his clinical and teaching roles and serves on several local committees.
Gianrico Farrugia, M.D.
Vice President of Mayo Clinic and CEO, Mayo Clinic in Florida
Dr. Gianrico Farrugia completed his undergraduate training at St. Aloysius College in Birkirkara, Malta, and received his M.D. at the University of Malta Medical School in 1987.
Dr. Farrugia is Vice President of Mayo Clinic and CEO of Mayo Clinic in Florida. He is a consultant in the Division of Gastroenterology and Hepatology and the Department of Physiology and Biomedical Engineering at Mayo Clinic in Rochester, Minnesota as well as a professor of medicine and physiology in the Mayo Clinic College of Medicine. He recently served as the director of the Mayo Clinic Center for Individualized Medicine.
Dr. Farurgia's research interests include genomics, the treatment of disorders of gastrointestinal motility, mechanosensitive ion channels, ion channel regulation, and a cell type known as the interstitial cell of Cajal. He has published more than 250 articles on these topics.
Dr. Farrugia's awards include top teacher awards, Mayo Clinic Research Career Achievement Award and the Janssen Award for Outstanding Science in Gastroenterology.
Stephen Friend, M.D., Ph.D.
President and Co-Founder, Sage Bionetworks
After receiving a Ph.D. in biophysics, Dr. Stephen Friend completed his clinical training at Children’s Hospital of Philadelphia and the Dana-Farber Cancer Research Institute in Boston. Dr. Friend was on the Harvard Medical School faculty from 1987-1995, Massachusetts General Hospital from 1990-1995 and University of Washington before becoming a Full Member at the Fred Hutchinson Cancer Research Center in 1995. He led the Whitehead Institute, Weinberg lab team to clone the first tumor suppressor gene p53 and characterized its role in controlling the cell cycle.
Dr. Friend and Dr. Leland Hartwell founded and co-led the 'Seattle Project', an institute that developed a method for examining large patterns of genes to provide detailed functional snapshots linking yeast and man and allowed researchers to intuit cellular activity directly from data. By 1997, the Seattle Project evolved into Rosetta Inpharmatics, a company co-founded with Dr. Leroy Hood. Rosetta developed cutting edge tools to generate and analyze high-dimensional functional genomics data, matching genetic variation and function to drug response. Merck & Company acquired Rosetta in 2001 and integrated its approach across the global pharmaceutical enterprise with Dr. Friend as Senior Vice President and Franchise Head for Oncology Research.
In 2009, Dr. Friend and Dr. Eric Schadt co-founded Sage Bionetworks, a non-profit organization with a goal to create a global integrative bionetwork community where researchers are rewarded for collaborating and sharing their data, knowledge and insights.
Dr. Friend continues to actively engage the community to crowd-source solutions to complex biomedical questions through targeted open DREAM analysis challenges.
Olga Golubnitschaja, M.D.
Head of the Division Molecular and Experimental Radiology, Department of Radiology, University of Bonn
Dr. Olga Golubnitschaja is on the medical faculty and head of the Department of Radiology of Bonn University. She has studied journalism, biotechnology and medicine and has been awarded fellowships for biomedical research in Pediatrics and Neurosciences in Austria, Russia, United Kingdom, Germany, Netherlands, and Switzerland.
Dr. Golubnitschaja is well-cited in the research fields of “gene hunting” and “subtractive hybridization” applied to predictive prenatal and postnatal diagnostics published as O.Labudova in 1990-2000. She is an expert in molecular diagnostics actively publishing in numerous fields. She is the co-founder of the Theory of Individual Patient Profiles, author of Fundamental Works in Systems Medicine - holistic approach considering molecular patterns at epi\genomic, transcriptional and post\translational levels.
Dr. Golubnitschaja holds appointments, at the rank of Professor, at several European universities and in International Programs for Personalized Medicine and has authored more than 300 international publications in the field.
Dr. Golubnitschaja is the recipient of numerous prestigious awards including the National & International Fellowship fo the Alexander von Humboldt-Foundation; Highest Prize in Medicine and Eiselsberg-Prize in Austria. She is Secretary-General of the European Association for Predictive, Preventive and Personalized Medicine and she is Advisor and Evaluator of projects dedicated to personalized medicine at the EU-Commission in Brussels, NIH/NCI, Washington D.C., and Foundations and National Ministries of Health in several European countries.
Rima Kaddurah-Daouk, Ph.D.
Associate Professor of Psychiatry and Behavioral Sciences, Duke University
Dr. Rima Kaddurah-Daouk received a Ph.D. in biochemistry from the American University in Beirut and completed a post-doctoral fellowship at the Johns Hopkins Medical School where she worked for two years with Nobel Laureate Dr. Hamilton Smith on the mechanism of protein-DNA recognition.
A co-founder of the Avicena Group, Dr. Kaddurah-Daouk has contributed significantly to the field of energy impairment in disease through her work on the creatine kinase system. With training at Johns Hopkins, Massachusetts General Hospital, Harvard Medical School, and the Massachusetts Institute of Technology, she is credited with several breakthrough inventions that are protected by a portfolio of more than 60 patents and patent applications. A number of these patents are recognized as the industry's earliest patent filings around creatine kinase and energy impairment and neurodegenerative diseases, as well as metabolomics.
Dr. Kaddurah-Daouk serves as the president of the Metabolomics Society, is an adjunct associate professor at Duke University Medical Center and maintains a research affiliation with the Dana Farber Cancer Institute. In addition to co-founding the Avicena Group, she is also credited as a co-founder of Metabolon, another leading biotechnology company.
Dr. Kaddurah-Daouk has key scientific publications in the field of energy impairment in disease. Her collaboration with Dr. M. Flint Beal and others at Harvard Medical School resulted in scientific discoveries that confirmed both the important role of creatine kinase in neuronal cell death and the beneficial effect of creatine supplementation for the potential treatment of ALS and other neurodegenerative diseases.
Konstantinos Lazaridis, M.D.
Professor of Medicine and Consultant in the Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine
Dr. Konstantinos Lazaridis is a Professor of Medicine and a Consultant in the Division of Gastroenterology and Hepatology at Mayo Clinic College of Medicine.
Dr. Lazaridis received his medical degree at the University of Ioannina in Greece. He completed his Internal Medicine and Gastroenterology fellowship training at Mayo Clinic and was a Mayo Clinic Scholar in Genomics in the laboratory of Dr. Francis Collins at the National Human Genome Research Institute.
Dr. Lazaridis is considered a leader in the area of the genomics of chronic cholestatic liver diseases, namely, Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Since 2003, he has established and is the principal investigator of the two national consortia for studying patients afflicted with these diseases. Supported by the NIH, Dr. Lazaridis and his research group apply the latest genomic and genetic epidemiology approaches to better understand these diseases and treatment methods.
As Associate Director of the Center for Individualized Medicine in Rochester, Dr. Lazaridis has been instrumental in the establishment and expansion of the Individualized Medicine Clinic and the direction of the Clinomics Translational Program.
Joshua Lewis, Ph.D.
Assistant Professor, University of Maryland School of Medicine
Dr. Joshua Lewis is an assistant professor in the Division of Endocrinology, Diabetes, and Nutrition as well as the Program for Personalized and Genomic Medicine at the University of Maryland School of Medicine. He received his Ph.D. in Molecular Genetics and Genomics at the Center of Genomics and Personalized Medicine Research at Wake Forest University.
Dr. Lewis’s research is identifying and functionally characterizing genes contributing to cardiovascular disease risk and translating genetic discoveries into individualized patient care through pharmacogenomics and/or other clinical approaches. His recent research has shown genetic variants in the Platelet Endothelial Aggregation Receptor 1 (PEARt) gene are associated with platelet reactivity and cardiovascular outcomes in patients on aspirin therapy. He is currently exploring the functional consequences of these polymorphisms in cellular models as well as in human populations.
Dr. Lewis is a member of the NIGMS-funded Pharmacogenomics Research Network and Pharmacometabolomics Research Network. He is the principal investigator of a Translational Scholar Career Award in Pharmacogenomics and Personalized Medicine to investigate the genetic underpinnings and mechanisms underlying aspirin and clopidogrel resistance as well as determining optimal antiplatelet dosing.
His honors include an NIH Extramural Clinical Research LRP Award, a Trainee Research Award from the American Society of Human Genetics, and a Training Fellowship in Cardiovascular Cell Biology from the National Heart, Lung, and Blood Institute.
Edison Liu, M.D.
President and CEO, Jackson Laboratory
Dr. Edison Liu obtained his B.S. in chemistry and psychology, as well as his M.D., at Stanford University.
Dr. Liu was the founding executive director of the Genome Institute of Singapore and President of the Human Genome Organization from 2007-2013. He held leadership positions as the Scientific Director of the National Cancer Institute's Division of Clinic Sciences, the director of the UNC Lineberger Comprehensive Cancer Center's Specialized Program of Research Excellence in Breast Cancer, the director of the Laboratory of Molecular Epidemiology at UNC's School of Public Health, chief of medical genetics, and Chair of the Correlative Science Committee of the National Cooperative Clinical Trials Group.
Dr. Liu is an international expert in cancer biology, genomics, human genetics, molecular epidemiology, and translational medicine. He served as Chairman of the Board of Singapore's Health Sciences Authority from 2007-2012 which is the Drug Regulatory Agency for the nation.
He is the recipient of the President's Medal of Singapore for his work to help resolve the SAR's crisis in Singapore and he has authored over 300 scientific papers and reviews, and co-authored two books.
Dr. Liu's current scientific research is focused on the functional genomics of human cancers, particularly breast cancer, uncovering new oncogenes, and deciphering the dynamics of gene regulation on a genomic scale that modulate cancer biology.
Patricia LoRusso, D.O.
Associate Director of Innovative Medicine, Professor of Medicine, Yale Cancer Center
Dr. Patricia LoRusso received her D.O from the Michigan State University School of Osteopathic Medicine and completed a fellowship in Medical Oncology with a focus on developmental therapeutics. She joined the faculty at Wayne State University School of Medicine in 1988. As a result of her focus on early therapeutics, she has come to be recognized as an international expert in the field of Phase 1 clinical research with a focus on novel trial design.
Recently, Dr. LoRusso joined Yale Cancer Center as a Professor of Medicine and Associate Director of Innovative Medicine. She has served as co-chair of the National Cancer Institute’s Cancer Therapy Evaluation Program Investigational Drug Steering Committee. She has served on the scientific committees of the American Society of Clinical Oncology, numerous peer-reviewed study sections, and NCI committees.
Dr. LoRusso has garnered many awards including the American College of Osteopathic Internists Researcher of the Year Award and the Hero of Breast Cancer award. In 2008, she was named one of Crain’s Detroit Business Health Care Heroes, was recognized with the Michaele C. Christian Oncology Drug Development Award and Lectureship from NCI CTEP.
Dr. LoRusso is a former editor of Investigational News Drugs, is currently on the editorial board for Clinical Cancer Research, and is a reviewer for several journals. She has authored more than 200 articles on cancer research in peer-reviewed journals, and written multiple book chapters.
Elizabeth Mansfield, M.D., Ph.D.
Deputy Office Director for Personalized Medicine in the Office of In Vitro Diagnostics and Radiological Health in the Center for Devices and Radiological Health
Dr. Elizabeth Mansfield received her Ph.D., from Johns Hopkins University and completed postdoctoral training at the National Cancer Institute and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases.
Dr. Mansfield has extensive experience in regulation and policy regarding in vitro diagnostic devices where she is developing a program to address companion and novel diagnostic devices. In addition, she has led the development of a personalized medicine program in CDRH.
Previously, Dr. Mansfield served as the Director of Regulatory Affairs at Affymetrix, Inc., 2004-2006, along with Scientific Reviewer, and Genetics Expert.
Jennifer McCormick, M.D., Ph.D.
Assistant Professor of Biomedical Ethics, Mayo Clinic
Dr. Jennifer McCormick is an Assistant Professor of Biomedical Ethics in the Departments of Medicine and Health Sciences Research. She received her doctorate degree in molecular and cellular biology. She received her Master’s degree in public policy from the University of Michigan. Before coming to Mayo Clinic in 2008, she was a fellow at the Stanford Center for Biomedical Ethics.
Dr. McCormick lectures frequently on topics related to research and translational ethics and directs Mayo Clinic’s graduate school course on Responsible Conduct of Research. She is a primary consultant on the CCaTs Clinical and Translational Research Ethics Consultation Service and works closely with clinical investigators and the IRB to enhance the quality of Mayo Clinic’s research protections.
Dr. McCormick’s scholarly interests focus on topics in research ethics and scientists understandings of policy and social responsibility in context of their work. She has published on topics related to research ethics consultation, genetic and genomic research and biobanking, human research participant engagement and protection, and challenges in translational research.
Dr. McCormick works closely with the Mayo Clinic Center for Individualized Medicine.
Tamas Ordog, M.D.
Associate Professor, Physiology, Mayo Clinic
Dr. Tamas Ordog is a Consultant and Associate Professor in the Department of Physiology and Biomedical Engineering and the Division of Gastroenterology and Hepatology at Mayo Clinic and founding Director of the Epigenomics Program of the Mayo Clinic Center for Individualized Medicine. He received predoctoral training in molecular endocrinology at the University of Pees, Hungary and postdoctoral training in integrative neuroendocrinology at the University of Texas Houston Health Science Center.
Dr. Ordog has studied the cellular and molecular basis of gastrointestinal neuromuscular control in health and disease since 1998. His current research interests include the epigenetic control of cellular phenotypes in the lineage of gastrointestinal pacemaker/neuromodulator cells in aging, diabetes, and caloric restriction and oncogenesis in response to targeted oncolytic therapy.
As Director of the Mayo Clinic CIM Epigenomics Program, he is leading the effort to implement epigenomic testing in the Individualized Medicine Clinic.
Eric Pamer, M.D.
Chief, Infectious Disease Service, Memorial Sloan-Kettering Cancer Center
Dr. Eric Pamer received his medical degree from Case Western Reserve University Medical School and completed clinical training in Internal Medicine and Infectious Diseases at UCSD Medical Center. Before moving to Yale University, he was a postdoctoral fellow with Charles E. Davis at UCSSD, Maggie So at Scripps Research Institute and Michael Bevan at the University of Washington.
In 2000, Dr. Pamer moved his laboratory to Memorial Sloan-Kettering Cancer Center in New York where he has been Chief of Infectious Disease and, more recently, Head of the Division of General Medicine.
Naveen Pereira, M.D., F.A.C.C.
Assistant Professor, Medicine and Pharmacology, Mayo Clinic College of Medicine
Dr. Naveen Pereira is a Consultant for the Division of Cardiovascular Diseases and Assistant Professor of Medicine and pharmacology, Mayo Clinic College of Medicine. He is board certified in Internal Medicine, cardiovascular diseases and advanced heart failure and transplant.
Dr. Pereira earned his medical degree at University of Bombay. He completed his internship and residency at the University of Connecticut and cardiac fellowship at the Brown University Hospital System and Massachusetts General Hospital.
Dr. Pereira received the Mayo Clinic Department of Medicine Career Development Award, the Marie Ingalls Cardiovascular Career Development Award, the Academic Research in Cardiology Award, the Transplant Center Scholarly Program Award, the Clinical Immunology and Immunotherapeutic Program Award and the Clinical and Translational Sciences KL2 Award with a focus on translating the genetics of pharmacotherapy.
Dr. Pereira served as Chairperson of the Standards and Guidelines Workforce of the International Society of Heart and Lung Transplantation. He is a member of the Functional Genomics and Translational Biology Council of the American Heart Association and is a member of the Circulation: Cardiovascular Genetics editorial board.
Dr. Pereira’s research interest include treatment of end-stage heart failure, antibody-mediated rejection in heart transplant, cardiac allograft hypertrophy, and genetics of the natriuretic peptide system and pharmacogenomics.
Eric Reiman, M.D.
Professor of Psychiatry, University of Arizona
Dr. Eric Reiman is Executive Director of the Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Professor of Psychiatry at the University of Arizona, University Professor of Neuroscience at Arizona State University, Clinical Director of Neurogenomics at the Translational Genomics Research Institute, and Director of the Arizona Alzheimer’s Consortium.
Dr. Reiman received his undergraduate and medical degrees at Duke University. He completed his psychiatry residency training at Duke University and Washington University and his introduction to brain imaging research at Washington University.
Dr. Reiman is internationally recognized for his contributions to brain imaging research, the behavioral neurosciences, and the presymptomatic study of Alzheimer’s disease. He has developed a strategy to find demonstrably effective treatment to prevent Alzheimer’s disease.
Dr. Reiman has authored more than 250 publications. He is a principal investigator of several NIH-supported research programs, and a leader of the Alzheimer’s Prevention Initiative.
Veronique Roger, M.D.
Professor of Epidemiology and Professor of Medicine, Mayo Clinic
Dr. Veronique Roger received her M.D., from the Paris, France Medical School and her M.P.H., from the Minnesota School of Public Health. At Mayo Clinic, she is a Professor of Internal Medicine, a Professor of Epidemiology, a cardiologist, an epidemiologist, and an outcomes researcher.
Dr. Roger’s research program focusing on the occurrence and outcomes of cardiovascular diseases is closely linked with the internationally recognized Rochester Epidemiology Project, and has been funded by the NIH since 1996.
Dr. Roger serves in several leadership roles within Mayo Clinic and is a member of the Mayo Clinic Board of Governors and Board of Trustees. In her role as Director of the Mayo Clinic Center for the Science of Health Care Delivery, Dr. Roger oversees several initiatives relevant to the research use of clinical data in the electronic health record environment including the Rochester Epidemiology Project and the High Value Health Care Collaborative.
Dr. Roger serves on national committees and task forces at the American Heart Association, the Institute of Medicine and the National Institutes of Health where she is a member of the National Heart, Lung and Blood Advisory Council.
Raul Urrutia, M.D.
Professor of Biophysics, Mayo Clinic
Dr. Raul Urrutia is Professor of Medicine, Biochemistry and Molecular Biology, and Biophysics at Mayo Clinic. He graduated Magna Cum Laude in 1987 from Cordoba University Argentina and pursued postdoctoral training at the National Institues of Health in Bethesda Maryland.
Dr. Urrutia established a laboratory at Mayo Clinic dedicated to studying chromatin dynamics and epigenetics as applied to metabolism and cancer. His laboratory discovered several HDAC, HATs, and HMTs pathways that associate with the development of diabetes and pancreatic cancer. His current work is focused on the functional characterization of HMT pathways, in particular G9a, GLP, SUV39H1, and EZH2.
Dr. Urrutia has published highly influential original articles, book chapters, reviews, and a widely cited textbook on pancreatic cancer. He has served as the Editor-in-Chief for three journals, Pancreatology, International Journal of Gastrointestinal Cancer, and Case Reports in Gastroenterology. He is a member of several editorial boards including the Journal of Biological Chemistry, Medical Epigenetics, and Pancreatology and Pancreas.
Dr. Urrutia served as President for the American Pancreatic Association, Chair for Pancreatic Diseases Section for the American Gastroenterological Association, and Chair for the International Association of Pancreatology board.